Stada’s Thornton & Ross UK subsidiary has launched a generic version of Seretide, known as Advair in the US, marking its first push into the respiratory arena.
Stada’s Thornton & Ross UK subsidiary has marked its “first launch into the UK respiratory disease market” by introducing a generic version of GlaxoSmithKline’s Seretide (salmeterol xinafoate/fluticasone propionate) dry powder inhaler under the name Fixkoh Airmaster.
The product is indicated for use in the regular treatment of asthma where use of a combination product, long-acting β2-agonist...
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
